BLIS Technologies Ltd
NZX:BLT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.9), the stock would be worth NZ$0.02 (18% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.6 | NZ$0.02 |
0%
|
| 3-Year Average | 1.9 | NZ$0.02 |
+18%
|
| 5-Year Average | 2.8 | NZ$0.03 |
+76%
|
| Industry Average | 4 | NZ$0.04 |
+149%
|
| Country Average | 1.8 | NZ$0.02 |
+10%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| NZ |
|
BLIS Technologies Ltd
NZX:BLT
|
20.5m NZD | 1.6 | 19.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 31.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6.7 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 5.7 | 27.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 6 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 5.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 1.7 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 6.3 | 16.6 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 1 |
| Median | 1.8 |
| 70th Percentile | 3.4 |
| Max | 11.6 |
Other Multiples
BLIS Technologies Ltd
Glance View
BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce Bacteriocin activity. The company is headquartered in Dunedin, Otago. The company went IPO on 2001-07-30. The firm is also engaged in supply of healthcare ingredients and the manufacture of part and finished goods and food products for sale in domestic and international markets. The firm supplies BLIS-branded finished goods. The firm's products include BLIS K12 and BLIS M18, which are oral probiotics providing protection for ear, nose and throat health, halitosis (bad breath), gums and teeth health and immune support. The firm distributes its products through Stratum Nutrition in North America, NZPR Group in China, and Bluestone Pharma in Europe and Middle East. Its other BLIS branded products include Throat Guard EVERYDAY BLIS K12, Travel Guard BLIS K12, Fresh Breath Kit K12 and Toddler Protect BLIS K12 Powder for Toddlers.
